Table 1. Animal model and clinical trial studies of LLLT on MS .

Year	Study	Intervention	Result
2016	Experimental autoimmune encephalomyelitis (EAE),	LLLT (AlGaInP, 660 nm and GaAs, 904 nm)	Reduced the clinical score, delayed disease onset, down-regulated NO
2016	120 MS patients	Wavelengths 650 nm and of power 50 mW generated by the device TERAPUS	Improved the functional status of patients
2019	Canine model of MS	MSC treated with LLLT	Increased remyelination, prevented the scar formation
2018	C57BL/6 mice	LLLT (36 J/cm2, 50 mW, 0.028 cm2 spot area)	Improved motor performance, attenuated demyelination
2019	19 MS patients	LLLT	Induced pain relief
2020	14 MS patients	Wavelength of 808nm, output power of 100 mW	Increased the level of IL-10, unchanged nitrite levels